Neuromyelitis Optica Spectrum Disorder (NMOSD) - Market Insights, Epidemiology and Market Forecast- 2027

Albany, NY -- (SBWire) -- 12/20/2018 --DelveInsight has announced the addition of the "Neuromyelitis Optica Spectrum Disorder (NMOSD) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of ATTR for the seven major markets i.e., United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan. The Report covers the overview, treatment practice and NMO/NMOSD forecasted epidemiology from 2018 to 2027 segmented by the seven major markets.
Request for sample pages

Neuromyelitis Optica Spectrum Disorder (NMO/NMOSD) is an autoimmune inflammatory disorder of the central nervous system in which the autoimmune system attacks myelin of the neurons located at the optic nerve and spinal cord, thus producing a simultaneous or sequential longitudinally extensive inflammation of the optic nerve (optic Neuritis) and spinal cord (myelitis). There are two forms of NMO/NMOSD: Relapsing and Monophasic. The relapsing form is most common and it is characterized by repeated attacks separated by periods of remission of optic neuritis and transverse myelitis. The monophasic form, which is less common, causes a single episode of Neuromyelitis Optica that can last several months. One or both optic nerves and the spinal cord are affected by a series of attacks over a short period of time (days or weeks) but, after the initial outburst, there is no recurrence. Signs and symptoms of Neuromyelitis Optica vary from person to person. Mild to severe symptoms develop depending on the affected parts of the body by Neuromyelitis Optica. It is more common in female as compared to male.

According to DelveInsight, total prevalent population of NMO/NMOSD in the 7 major was 32,382 cases in 2016 during the study period [2016-2027]. A total of 13,212 monophasic and 6,217 recurrent event cases of NMO/NMOSD were diagnosed in 2016 in 7MM. DelveInsight also estimates higher prevalence of NMO/NMOSD in the United States in 2016. Among the European countries, Germany had the highest prevalent population of NMO/NMOSD, followed by France. DelveInsight estimates that the diagnosed prevalent population of NMO/NMOSD will significantly increase during the study period [2016-2027]. NMO/NMOSD is classified into transverse myelitis and optic neuritis, according to Mealy M et al, all NMO/NMOSD patients had a history of optic neuritis and transverse myelitis. Optic neuritis averaged 1.8 events and 0.8 events per year.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan
Study Period: 2016-2027

Drug Companies

1. Alexion Pharma
2. Chugai Pharmaceutical/ Roche
3. Viela Bio
And many others

Drugs covered

1. Soliris
2. Satralizumab (SA237)
3. MEDI-551
And many others

Report Scope

The report covers the descriptive overview of NMO/NMOSD explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. Comprehensive insight has been provided into the epidemiology of the NMO/NMOSD and its treatment in the 7 MM, covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for NMO/NMOSD are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted NMO/NMOSD market is included in the report, covering drug outreach in the 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global NMO/NMOSD market